Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Inclusion Criteria: Angiography demonstrating atherosclerosis amenable to treatment by percutaneous coronaryintervention (PCI) with or without stent implantation and diagnosis of Acute CoronarySyndrome (ACS) by elevated cardiac markers or ischemic chest discomfort w/electrocardiogramchanges + age > 65 or diabetes.

Exclusion Criteria:

1. Not a candidate for PCI

2. ST-segment elevation myocardial infarction (STEMI) within 48 hours of randomization

3. Increased bleeding risk: ischemic stroke within the last year or any previoushemorrhagic stroke, intra-cranial tumor, cerebral arteriovenous malformation, orintracranial aneurysm; recent (<1 month) trauma or major surgery [including coronaryartery bypass graft (CABG) surgery]; currently receiving warfarin, active bleeding

4. Impaired hemostasis: known International Normalized Ratio (INR) >1.5 at screening;past or present bleeding disorder (including congenital bleeding disorders such as vonWillebrand's disease or hemophilia, acquired bleeding disorders, and unexplainedclinically significant bleeding disorders), thrombocytopenia (platelet count <100,000/µL) at screening

5. Severe hypertension not adequately controlled by antihypertensive therapy at the timeof randomization

6. Receipt of fibrinolytic therapy in the 12 hours preceding randomization

7. Receipt of any thienopyridine (clopidogrel or ticlopidine) in the 7 days precedingrandomization

8. Glycoprotein IIb/IIIa (GPI) Inhibitor usage within the previous 12 hours [applicableto unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) patients]